Cellectar Biosciences (CLRB) vs Passage Bio (PASG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Passage Bio (PASG) has outperformed Cellectar Biosciences (CLRB) over the past year, losing 54.3% versus a loss of 70.7%. Over five years, PASG leads with a -98.1% price change compared with -99.5% for CLRB. Cellectar Biosciences is the larger company by market cap ($13.2 million vs $12.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLRB | PASG |
|---|---|---|
| Share price | $1.40 | $3.78 |
| Market cap | $13.23M | $12.16M |
| 1-day change | -7.28% | -1.95% |
| YTD return | -52.54% | -67.97% |
| 1-year return | -70.71% | -54.35% |
| 5-year return | -99.49% | -98.06% |
| EPS (TTM) | $-3.46 | $-11.33 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.07 | $20.00 |
| 52-week low | $1.34 | $3.29 |
| Distance from 52-week high | -72.39% | -81.10% |
| Analyst consensus | none | buy |
| Avg. price target upside | +721.43% | +310.05% |
| Average volume | 63.86K | 26.11K |
| Shares outstanding | 9.45M | 3.22M |
| Employees | 11 | 24 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PASG has outperformed CLRB by 16.4 percentage points over the past year.
About Cellectar Biosciences
CLRB stock →Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer.
Healthcare · Biotechnology · 11 employees
About Passage Bio
PASG stock →Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease.
Healthcare · Biotechnology · 24 employees
CLRB vs PASG FAQ
Which is bigger, Cellectar Biosciences or Passage Bio?
Cellectar Biosciences (CLRB) is larger, with a market capitalization of $13.23M compared with $12.16M for Passage Bio (PASG).
Which stock has performed better over the past year, CLRB or PASG?
PASG returned -54.35% over the past 12 months, compared with -70.71% for CLRB (price return, excluding dividends). Past performance does not predict future results.
Are Cellectar Biosciences and Passage Bio in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.